Royal Bank of Canada
ESLA icon

Royal Bank of Canada’s Estrella Immunopharma ESLA Stock Holding History

Royal Bank of Canada’s Portfolio ESLA Stock Details ESLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7K Hold
6,600
– – ﹤0.01% 6311
2025
Q4 		$10K Buy
+6,600
New +$12.5K ﹤0.01% 6408

Other funds holding ESLA

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Royal Bank of Canada's ESLA Position: Q1 2026 in Review

Royal Bank of Canada held its Estrella Immunopharma (ESLA) position steady in Q1 2026 at 6,600 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #6311.

Royal Bank of Canada first reported a position in ESLA in Q4 2025 and has held it in 2 quarters since. The position peaked at $10K in Q4 2025. 16 funds tracked by Wall St. Rank hold ESLA as of Q1 2026.

  • Royal Bank of Canada held 6,600 shares of Estrella Immunopharma worth $7K as of Q1 2026.
  • Royal Bank of Canada left its Estrella Immunopharma share count unchanged in Q1 2026.
  • Estrella Immunopharma made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6311 holding.
  • Royal Bank of Canada first reported a position in Estrella Immunopharma in Q4 2025 and has held it in 2 quarters since.
  • Royal Bank of Canada's Estrella Immunopharma position peaked at $10K in Q4 2025.
  • 16 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.